Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Dec 1;214(11):1695-1699.
doi: 10.1093/infdis/jiw439. Epub 2016 Sep 22.

Hepatitis B Virus (HBV) Load Response to 2 Antiviral Regimens, Tenofovir/Lamivudine and Lamivudine, in HIV/ HBV-Coinfected Pregnant Women in Guangxi, China: The Tenofovir in Pregnancy (TiP) Study

Liming Wang  1   2   3 , Jeffrey Wiener  4 , Marc Bulterys  1   5 , Xiaoyu Wei  1 , Lili Chen  6 , Wei Liu  7 , Shujia Liang  7 , Colin Shepard  1   5 , Linhong Wang  8 , Ailing Wang  8 , Fujie Zhang  2   3   9 , Athena P Kourtis  4
Affiliations
Clinical Trial

Hepatitis B Virus (HBV) Load Response to 2 Antiviral Regimens, Tenofovir/Lamivudine and Lamivudine, in HIV/ HBV-Coinfected Pregnant Women in Guangxi, China: The Tenofovir in Pregnancy (TiP) Study

Liming Wang et al. J Infect Dis. .

Abstract

Background: There is limited information on antiviral therapy for hepatitis B virus (HBV) infection among pregnant women coinfected with human immunodeficiency virus (HIV) and HBV.

Methods: A phase 2 randomized, controlled trial of a regimen containing tenofovir (TDF)/lamivudine (3TC) and a regimen containing 3TC in HIV/HBV-coinfected pregnant women in China. The HBV virological response was compared in study arms.

Results: The median decline in the HBV DNA level was 2.60 log10 copies/mL in the TDF/3TC arm and 2.24 log10 copies/mL in the 3TC arm (P = .41). All women achieved HBV DNA levels of <6 log10 copies/mL at delivery.

Conclusions: Initiation of either regimen led to achievement of HBV DNA levels below the threshold associated with perinatal HBV transmission.

Clinical trials registration: NCT01125696.

Keywords: HBV DNV viral load; HBV suppression; HIV/HBV coinfection; lamivudine; pregnancy; tenofovir.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Hepatitis B virus (HBV) loads from baseline to delivery among pregnant women coinfected with human immunodeficiency virus and HBV, by study arm, in the Tenofovir in Pregnancy study. Abbreviation: HBeAg, HBV e antigen.
See this image and copyright information in PMC

References

    1. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection–a global challenge. N Engl J Med 2012; 366:1749–52. - PMC - PubMed
    1. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7:402–9. - PubMed
    1. Thio CL, Locarnini S. Treatment of HIV/HBV coinfection: clinical and virologic issues. AIDS Rev 2007; 9:40–53. - PubMed
    1. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27:6550–7. - PubMed
    1. Xu H, Zeng T, Liu JY, et al. Measures to reduce mother-to-child transmission of hepatitis B virus in China: a meta-analysis. Dig Dis Sci 2014; 59:242–58. - PubMed

Publication types

Associated data